The current collaboration yielded significant results with a new design platform, which has helped scientists increase the flow of potential discovery leads tenfold. The new phase of the collaboration builds on this order of magnitude increase in research productivity and extends the platform with a powerful software module for industrial-scale cloning. In building a flexible modular platform and not a custom solution, the companies are rigorous about building software modules that adhere to a strict design-build-test methodology with a strong emphasis on repeatability and architecture suitable for machine learning.
“Implementing a secure computational environment to design and create molecular biology research information will accelerate our scientists’ efforts to find new crop protection and seed products for farmers around the world,” said Otto Folkerts, Ph.D., Research Fellow, Dow AgroSciences.
“TeselaGen is building a platform that automates and optimizes protocol generation and information flow for biomanufacturing. Our hypothesis is that biotechnology is essentially an information technology. Improving the flow, handling and interpretation of information is a tremendous accelerant for biotech product development,” said Dr. Michael Fero, Chief Executive Officer, TeselaGen.
Terms of the collaboration were not disclosed.
About Dow AgroSciences
Dow AgroSciences discovers, develops, and brings to market crop protection and plant biotechnology solutions for the growing world. Based in Indianapolis, Indiana, USA, Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company and had annual global sales of $6.2 billion in 2016. Learn more at www.dowagro.com. Follow Dow AgroSciences on Facebook, Twitter, LinkedIn, and Google+, or subscribe to our News Release RSS Feed.
TeselaGen builds secure enterprise quality software platforms for designing, building and precision editing DNA, enabling the development of vaccines, biologic medicines, and sustainably sourced chemicals. TeselaGen is privately held and is based in the software hub of San Francisco, CA. The company has received early recognition in the form of four US National Science Foundation funding awards, a US Department of Energy funding award and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for efficient rapid prototyping and editing of recombinant molecules. Follow TeselaGen on Facebook, Twitter, LinkedIn, and Google+, and learn more at teselagen.com.